A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Dana-Farber Cancer Institute
City of Hope Medical Center
M.D. Anderson Cancer Center
IGM Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
GSO Global Clinical Research BV
AstraZeneca
Massachusetts General Hospital
Eli Lilly and Company
UNC Lineberger Comprehensive Cancer Center
Sanofi
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)